Protection against exercise-induced muscle damage by 8 weeks of Omega-3 supplementation in older adults.
- Conditions
- Inflammation
- Registration Number
- DRKS00032985
- Lead Sponsor
- German Institute of Human Nutrition Potsdam-Rehbrücke
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 44
Age: 65-85
- BMI between 22-30 kg/m²
- Active smokers
- Athletes
- Atrial fibrillation, known/past cardiac arrhythmias or heart attacks
- Arterial hypertension (resting blood pressure > 140/90 mmHg)
- Taking blood lipid-lowering drugs (statins), antiarrhythmics (such as flecainide, propafenone, amiodarone, dronedarone) and anticoagulant medications (such as Apixaban, Marcumar)
- Food intolerances/allergies to seafood or algae
- Taking dietary supplements containing polyunsaturated fatty acids, including omega-3 fatty acids
- Diagnosed with diabetes mellitus
- Presence of malignant neoplasms, HIV
- self-reported serious diseases of the cardiovascular system such as arteriosclerosis or advanced heart disease (NYHA grade =2 (New York
Heart Association” classification)), acute respiratory diseases or
severe chronic lung diseases (COPD; GOLD stage =2 (Global
Initiative for Chronic Obstructive Lung Disease” classification))
- self-reported severe liver, kidney or metabolic diseases, such as liver cirrhosis (Child Pugh Score =2) or renal insufficiency (stage =3)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Isometric force loss of the quadriceps following 100 repetitions leg extensions after eight weeks, determined from the quadriceps strength changes on examination days 3, 4 and 5.
- Secondary Outcome Measures
Name Time Method Inflammation after 8 weeks in comparison to baseline, determination of IL-6 and CRP concentrations in the blood using ELISA